ArticleToxins2015
Recommended Immunological Assays to Screen for Ricin-Containing Samples.
Article in Toxins, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- Polyclonal antibodies towards abrin and ricin-design and potential application for mass spectrometry-based analysis of human biosamples.Archives of toxicology · 2025Article
- Rapid and Highly Sensitive Detection of Ricin in Biological Fluids Using Optical Modulation Biosensing.Biosensors · 2025Article
- Article
- Rapid detection of ricin at trace levels in complex matrices by asialofetuin-coated beads and bottom-up proteomics using high-resolution mass spectrometry.Analytical and bioanalytical chemistry · 2024Article
- Mass Spectrometric Detection and Differentiation of Enzymatically Active Abrin and Ricin Combined with a Novel Affinity Enrichment Technique.Chemical research in toxicology · 2024Article
- Article
- Medical Countermeasures against Ricin Intoxication.Toxins · 2023Review
- Article
- End-Functionalized Poly(vinylpyrrolidone) for Ligand Display in Lateral Flow Device Test Lines.ACS polymers Au · 2022Article
- Functional magnetic nanoparticle-based affinity probe for MALDI mass spectrometric detection of ricin B.Mikrochimica acta · 2021Article
- [Highly toxic type Ⅱ ribosome-inactivating proteins ricin and abrin and their detection methods: a review].Se pu = Chinese journal of chromatography · 2021Review
- Review
- Article
- An International Proficiency Test to Detect, Identify and Quantify Ricin in Complex Matrices.Toxins · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ricin, a toxin from the plant Ricinus communis, is one of the most toxic biological agents known. Due to its availability, toxicity, ease of production and absence of curative treatments, ricin has been classified by the Centers for Disease Control and Prevention (CDC) as category B biological weapon and it is scheduled as a List 1 compound in the Chemical Weapons Convention. An international proficiency test (PT) was conducted to evaluate detection and quantification capabilities of 17 expert laboratories. In this exercise one goal was to analyse the laboratories' capacity to detect and differentiate ricin and the less toxic, but highly homologuous protein R. communis agglutinin (RCA120). Six analytical strategies are presented in this paper based on immunological assays (four immunoenzymatic assays and two immunochromatographic tests). Using these immunological methods "dangerous" samples containing ricin and/or RCA120 were successfully identified. Based on different antibodies used the detection and quantification of ricin and RCA120 was successful. The ricin PT highlighted the performance of different immunological approaches that are exemplarily recommended for highly sensitive and precise quantification of ricin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.